Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BridgeBio
Biotech
BridgeBio touts case for acoramidis with post hoc study analysis
Acoramidis reduced the total number of all-cause mortality and recurrent cardiovascular hospitalization events by 42% compared to placebo.
Darren Incorvaia
Sep 30, 2024 9:37am
BridgeBio’s offshoot GondolaBio launches with $300M
Aug 21, 2024 11:36am
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
May 3, 2024 8:30am
BridgeBio bags $250M in stock sale before acoramidis submission
Sep 25, 2023 11:20am
BridgeBio heart disease med vindicated with phase 3 victory
Jul 17, 2023 10:12am
BridgeBio's phase 2 data provides hope for rare disease drug
Jun 14, 2022 8:20am
